| CDC Recommends New Injectable HIV PrEP |
Webpage (HTML) |
Centers for Disease Control and Prevention |
| Cabotegravir injections for PrEP |
Webpage (HTML) |
aidsmap |
| FDA approval of Yeztugo |
Webpage (HTML) |
Gilead |
| Fact sheet Lenacapavir and long-acting injectable PrEP |
Webpage (HTML) |
PAHO |
| Helping you access your Injectable PrEP |
Webpage (HTML) |
Advancing Access |
| Injectable Cabotegravir for PrEP |
Webpage (HTML) |
PrEP Watch |
| Injectable HIV Treatment and PrEP |
Webpage (HTML) |
East Bay Getting to Zero |
| Injectable PrEP Frequently Asked Questions-Clinical |
Webpage (HTML) |
CAPTC |
| LEN Rollout Resources and Tools |
Webpage (HTML) |
PrEP Watch |
| Lenacapavir Provider Tools and Job Aids |
Webpage (HTML) |
PrEP Watch |
| Long-Acting HIV Prevention Tools |
Webpage (HTML) |
HIV.gov |
| Long-Acting Injectable PrEP |
Webpage (HTML) |
NASTAD |
| Patient Information |
Webpage (HTML) |
Long Acting Agent Resource |
| Simplifying Prevention: A Deep Dive into Long Acting Injectable PrEP |
Webpage (HTML) |
Health HIV |
| What is cabotegravir? |
Webpage (HTML) |
Clinicalinfo.HIV.gov |
| What is lenacapavir? |
Webpage (HTML) |
Clinicalinfo.HIV.gov |
| What is the most important thing I should know about APRETUDE? |
Webpage (HTML) |
ViiV Healthcare |
